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Abstract Evidence suggests that p53 induces cell death by a
dual mode of action involving activation of target genes and
transcriptionally independent direct signaling. Mitochondria are
major signal transducers in apoptosis. We recently discovered
that a fraction of induced p53 protein rapidly translocates to
mitochondria during p53-dependent apoptosis, but not during
p53-independent apoptosis or p53-mediated cell cycle arrest.
Importantly, specific targeting of p53 to mitochondria was
sufficient to induce apoptosis in p53-deficient tumor cells. This
led us to propose a model where p53 exerts a direct apoptogenic
role at the mitochondria, thereby enhancing the transcription-
dependent apoptosis of p53. Here we show for the first time that
mitochondrial localization of endogenous p53 can be visualized
by immunofluorescence of whole cells when stressed by hypoxic
conditions. Suborganellar localization by limited trypsin diges-
tion of isolated mitochondria from stressed cells suggests that a
significant amount of mitochondrial p53 is located at the surface
of the organelle. This mitochondrial association can be
reproduced in vitro with purified p53. Together, our data provide
further evidence for an apoptogenic signaling role of p53 protein
in vivo at the level of the mitochondria. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Despite its central role in cell death, the mechanism of p53-
mediated apoptosis after cellular stress remains unclear. Cur-
rent evidence indicates that p53 induces cell death by a com-
plex dual mode of action involving transactivation of target
genes and direct signaling events which are transcription-in-
dependent (reviewed in [1,2]). With respect to the transactiva-
tion mode, which is the better studied, a growing and diverse
list of p53-inducible genes are candidates for participating in
p53’s apoptotic action. These include target genes with proven
roles in apoptotic pathways such as the death receptors Fas/
APO-1 [3,4] and KILLER/DR5 [5] and target genes whose
products act directly on mitochondria such as Bax [6], Noxa
[7] and p53 apoptosis-inducing protein 1 [8]. In addition,
genes with less well de¢ned apoptotic roles such as the PIG
redox-modulators [9] and the p85 regulatory subunit of phos-
phatidyl-3-OH kinase [10] have also been proposed. This ar-
ray of potential targets likely have cell type and death stim-
ulus speci¢city. It is also in sharp contrast to the few response
genes through which p53 mediates cell cycle arrest (e.g. Waf1
and 14-3-3s) and indicates that p53 does not rely on any one
of these downstream e¡ectors alone to exert its powerful
death role.
Evidence for an additional transcription-independent path-
way for p53-mediated apoptosis is accumulating. In some cell
types, p53-dependent apoptosis occurs in the absence of gene
transcription or protein synthesis [11^13] or upon expression
of the transcriptionally inactive mutants p53 (1-214) [14,15]
and p53 Gln-22,Ser-23 [16]. In addition, a tumor-derived
p53 mutant exists (p53 R175P) that transactivates p53 targets
involved in cell cycle arrest but is defective for apoptosis [17].
This indicates that the transactivation activity of p53 is not
su⁄cient for an apoptotic response and suggests that p53 can
induce apoptosis through a transcription-independent mecha-
nism. In vascular smooth muscle cells, p53 protein can medi-
ate apoptosis by directing Fas redistribution from the Golgi
complex to the cell surface [18]. Most interestingly, p53 pro-
tein from cell-free postnuclear cytosolic extracts which still
contain mitochondria mediates the activation of e¡ector cas-
pases in cells undergoing p53-dependent apoptosis [19]. This
indicates a transcription-independent p53 action and suggests
protein^protein signaling from p53 to the Casp9/Casp3 cas-
cade.
Mitochondria are central integrators and transducers for
pro-apoptotic signals. This is particularly but not exclusively
the case with those inducers of cell death that activate apo-
ptosis independently of death receptor pathways. Such in-
ducers include cell damage from g-IR, anticancer drugs, hyp-
oxia and growth factor withdrawal. A major reason for the
central role of mitochondria is that these organelles store crit-
ical apoptotic activators and e¡ectors of cell death in their
intermembranous space. These include cytochrome c, Smac/
Diablo (a caspase co-activator), apoptosis-inducing factor
which activates nuclear endonucleases and procaspases 2
and 9 ([20^23] ; reviewed in [24,25]). Permeabilization of mi-
tochondrial membranes causes the release of these activators
and triggers the killing of cells.
Recently we showed that a fraction of induced p53 protein
directly translocates to mitochondria in response to death
signals from anticancer drugs [26]. This translocation is spe-
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ci¢c for p53-dependent apoptosis but not for p53-independent
apoptosis or for p53-dependent arrest and occurs in a variety
of non-malignant and malignant human and mouse cells. In-
duced p53 translocation is rapid (1 h) and precedes changes in
mitochondrial membrane potential, cytochrome c release and
procaspase 3 activation. Ectopic overexpression of anti-apo-
ptotic bcl-2 or bcl-xL abrogates stress-induced p53 transloca-
tion to mitochondria and apoptosis but does not abrogate
stress-induced cell cycle arrest. Most importantly, speci¢c tar-
geting of p53 to mitochondria is su⁄cient to cause cell death.
The mitochondrial p53 action is transcription-independent
since targeted mutant p53 R175H, which is completely inac-
tive as a nuclear version, remains active as a mitochondrial
protein. We therefore proposed that this apoptogenic mito-
chondrial action of p53 enhances the transcriptional action of
p53 to mediate cell death [26].
Previously we used subcellular fractionation and immuno-
electronmicroscopy of isolated mitochondria to show the
stress-induced mitochondrial p53 translocation. The purpose
of the current study was to substantiate these ¢ndings by
direct visualization of mitochondrial p53 in whole cells, to
test this mitochondrial p53 association in vitro and to identify
the major suborganellar compartment of p53 localization. We
¢nd that short term hypoxia treatment provides a brief win-
dow in time before the protein accumulates in the nuclei,
which is optimal for visualizing mitochondrial staining of
p53 in whole cells. Moreover, we show that puri¢ed p53 spe-
ci¢cally associates with mitochondria in vitro. Suborganellar
localization studies using limited trypsin digestion suggest that
the majority of mitochondrial p53 locates to the surface of
mitochondria.
2. Materials and methods
2.1. Cell culture
Human ML-1 cells, harboring wild type (wt) p53, were grown in
DMEM supplemented with 10% fetal bovine serum. Camptothecin
(Sigma) was added to freshly seeded cultures. For hypoxic conditions,
freshly seeded cells were placed into GasPak plastic pouches (BBL
GasPak Pouch Systems, Becton Dickinson), tightly sealed and placed
back into the incubator for the indicated times. The pouches contain
an iron-based oxygen consuming chemical, an O2 indicator strip and a
carbon dioxide generator. As certi¢ed by the manufacturer, they gen-
erate a CO2-enriched hypoxic microenvironment with an oxygen con-
centration of 6 2% and a CO2 concentration of s 4% within 2 h of
incubation.
Alternatively, hypoxia conditions were generated by adding
deferoxamine mesylate (DXE, Sigma) into the culture medium for
the indicated times.
2.2. Preparation of mitochondrial fractions
Mitochondria were prepared by sucrose density gradients as we
previously described [27]. Mitochondria were collected at the
1^1.5 M interphase by lateral suction, washed in four volumes of
MS bu¡er (210 mM mannitol, 70 mM sucrose, 5 mM Tris pH 7.6,
5 mM EDTA), pelleted at 14 000 rpm for 10 min and carefully resus-
pended in a ¢nal volume of 200 Wl MS bu¡er. Limited trypsin diges-
tion of mitochondrial fractions and crude cell lysates (75 Wg protein/50
Wl MS bu¡er) was performed as described [28] at room temperature
for 10 and 20 min using TPCK-treated trypsin (Sigma) at a ratio of
1:500 trypsin:total protein. For in vitro assays of mitochondrial p53
association, mitochondria from untreated ML-1 cells were freshly
prepared by sucrose density gradients as above. Isolated mitochondria
(37 Wg total protein) were incubated with 60 ng of puri¢ed baculoviral
human wt p53 (untagged, puri¢ed by sequential MonoQ columns to
obtain a single band by silver gel), or with 60 ng of puri¢ed recombi-
nant (Escherichia coli) human wt PCNA (6U His-tagged, puri¢ed by
Ni-NTA metal a⁄nity column, Qiagen) for 1 h at 37‡C in MS bu¡er
containing 150 WM CaCl2. Mitochondria were pelleted (14 000 rpm
for 10 min) and washed three times in 1 ml of MS bu¡er each prior to
SDS^PAGE.
2.3. Immuno£uorescence
ML-1 cells were either left untreated or hypoxia-treated for 6 h
(GasPak pouches or 125 WM deferoxamine). 30 min before ¢xation,
all cells were in vivo labeled by adding 50 nM Mito Tracker Red
CMXRos (Molecular Probes) into the medium. To test for speci¢city
of Mito Tracker staining, cells were pretreated for 10 min with the
uncoupler FCCP (50 nM) (carbonyl cyanide p-(tri-£uoromethoxy)-
phenyl-hydrazone) prior to labeling with Mito Tracker as above.
Cells were quickly cytospun onto glass slides, ¢xed for 3 min with
ice cold 1:1 acetone/methanol, washed and blocked in 10% goat se-
rum followed by CM-1 (rabbit anti-human p53, 1:500). After wash-
ing, cells were incubated with biotinylated goat anti-rabbit IgG fol-
lowed by streptavidin-conjugated FITC (1:200 in blocking solution)
(Zymed Labs, San Francisco, CA, USA) and mounted with glycerol-
free SlowFade (Molecular Probes).
2.4. Immunoblot and apoptosis assays
Equal amounts of total protein of mitochondrial or crude cell ly-
sates (10^25 Wg) were subjected to Western blot analysis and devel-
oped with enhanced chemiluminescence (Amersham) for 15^60 s. The
following antibodies were used: monoclonal DO-1 (Calbiochem) for
human p53; monoclonal mt hsp60 and mt hsp70 (A⁄nity Biore-
agents); monoclonal PCNA (Santa Cruz); monoclonal cytochrome
c (Pharmingen), cytochrome oxidase IV (Molecular Probes) and poly-
clonal bcl-xL (Santa Cruz). Apoptosis was assessed by the in situ
TUNEL assay (Boehringer).
3. Results
3.1. Short term hypoxic stress induces mitochondrial p53
detectable by immuno£uorescence of whole cells
We recently showed that a fraction of death signal-induced
p53 localizes to mitochondria [26]. This phenomenon is wide-
spread and occurs in human and mouse non-malignant and
malignant cells in response to various types of stress such as
DNA damage by various topoisomerase inhibitors (e.g. camp-
tothecin). Here we further explore p53 localization to mito-
chondria in response to hypoxia in ML-1 cells. ML-1 cells are
a human chronic myelogenous leukemia line harboring wt p53
which is functionally fully competent [26]. To this end, highly
enriched mitochondrial fractions from ML-1 cells before and
after apoptosis induction were prepared by classic discontin-
uous sucrose gradients [27] and analyzed by immunoblots.
Mitochondrial fractions prepared in this fashion are over
90% pure by electronmicroscopy and have only minimal con-
tamination by other subcellular fractions as we previously
showed by marker studies (see [26]). Most importantly, they
are almost completely devoid of nuclear contamination as
assessed by PCNA (Fig. 1A,C). Fig. 1A shows that hypoxia
generated by a high dose of the hypoximimetic deferoxamine
(DXE) (250 WM for 8 h) induces a similar degree of mitochon-
drial p53 as does the DNA damaging drug camptothecin (5
WM for 8 h) (compare lane 2 with lanes 4 and 6). The total
cellular p53 induction by DXE (‘crude’), re£ecting mainly
nuclear p53, is somewhat less than after camptothecin damage
(lanes 1, 4 and 6).
To directly localize p53 to mitochondria of early apoptosing
cells, we performed indirect immuno£uorescence. Our earlier
attempts with ML-1 cells using 8 h exposure to camptothecin,
which induces double strand breaks, or to high dose DXE,
showed intense nuclear staining but did not reproducibly de-
tect the proportionately low levels of mitochondrial p53 due
to interference by cytoplasmic background and the intensely
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staining large nuclei in these cells. By switching to milder
hypoxic conditions (generated by hypoxic GasPak pouches
or by lowering the dose of deferoxamine to 125 WM) and by
decreasing the time of exposure, we determined that a narrow
window exists at 6 h after treatment initiation when ML-1
cells are showing a punctate cytoplasmic p53 staining but
have not yet induced strong nuclear staining, which would
interfere with the narrow rim of cytoplasmic staining (Fig.
1B, left column, compare treated with untreated conditions).
This punctate staining shows signi¢cant colocalization with
mitochondria (Fig. 1B, yellow £uorescence). The requirement
for optimized timing and stress conditions might explain why
mitochondrial p53 escaped previous detection. To indepen-
dently con¢rm mitochondrial localization of p53, we repeated
the subcellular fractionation after 6 h of mild hypoxia and
again could detect a p53 band in the mitochondrial fraction
after treatment (Fig. 1C, compare lanes 2 and 4). Both modes
of hypoxia (125 WM DXE or GasPak) induced the transcrip-
tional activity of p53 as seen by p21 upregulation after 16 h
(data not shown and [29]). TUNEL assays showed that hyp-
oxia treatment of ML-1 cells induced greater than 80% cell
death after 24 h of 125 WM deferoxamine (Fig. 1D). Together
with the induction of cellular p53 (Fig. 1A,C), this indicates
that hypoxia-mediated apoptosis in ML-1 cells has a signi¢-
cant p53-dependent component.
3.2. The majority of mitochondrial p53 is located on the surface
of the organelle
Using isolated mitochondria we previously showed by im-
munogold electronmicroscopy that the majority of the stress-
induced mitochondrial p53 appears to be located on the sur-
face of the organelle, while a small subfraction formed an in
vivo complex with the import protein mt hsp70 [26]. To sup-
port this result biochemically, we performed a classical mito-
chondrial import assay using limited protease digestion. After
subjecting mitochondrial isolates from stressed cells to con-
trolled trypsin digestion which removes proteins attached to
the outside of the organelle [30], the majority of the associated
p53 protein was digested after 10 min, as indicated by the
drastic decrease in band intensity of full length p53 and the
novel appearance of a cleaved p53 fragment (Fig. 2, compare
lane 2 with lane 4). Bcl-xL protein, located on the outer mi-
tochondrial membrane, served a positive control for this as-
say. Bcl-xL was digested with similar kinetics as p53. In con-
trast, cytochrome c, which resides in the intermembranous
Fig. 2. The majority of mitochondrial p53 locates to the surface of
the organelle. Trypsin digestion of isolated mitochondria treated
with camptothecin (5 mM for 5 h). Immunoblot of digests after 0,
10 and 20 min probed with speci¢c antibodies for p53, bcl-xL and
cytochrome c. The majority of mitochondrial p53 is unprotected
and cleaved after 10 min, as is the outer membrane protein bcl-xL,
while a small portion is protected, suggesting import (lanes 4 and
6). The intermembranous protein cytochrome c is protected.
Fig. 1. A: Hypoxia generated by deferoxamine induces a similar de-
gree of mitochondrial p53 as does DNA damage by camptothecin.
Immunoblot of crude cell lysates and mitochondrial fractions before
(C) and after treatment with camptothecin (5 WM, 8 h) or deferox-
amine (250 WM, 8 h). PCNA is a marker for nuclear contamination.
B: Short term hypoxic stress induces mitochondrial p53 detectable
by immuno£uorescence. Colocalization of p53 and mitochondria in
the early phase of hypoxia. ML-1 cells untreated or after 6 h of
hypoxia (125 WM deferoxamine or GasPak pouches GPP) were in
vivo labeled with the mitochondria-speci¢c potentiometric dye Mito
Tracker, followed by immuno£uorescence for p53 with CM-1. Con-
focal Nikon Diaphot 200 Inverted Microscope. All images were
taken with identical acquisition parameters (laser intensity, photo-
multiplier, and Photoshop Software settings) at U60 original magni-
¢cation. The fourth row shows two cells captured at a resolution
which visualizes individual mitochondria (zoomed in with Bio-Rad
LaserSharp Software 2000). Colocalization is indicated in yellow.
Bottom: when ML-1 cells were pretreated for 10 min with an un-
coupler of oxidative phosphorylation (50 nM FCCP), Mito Tracker
accumulation in mitochondria was greatly suppressed. C: Immuno-
blot of subcellular fractionation after short term hypoxia. A p53
band is detected in the mitochondrial fraction after 6 h of hypoxia
(GasPak pouches). Control cells were left untreated. mt hsp60 is a
mitochondrial and PCNA is a nuclear marker. D: Percentage of
apoptosis of ML-1 cells induced by 125 WM deferoxamine after the
indicated times. TUNEL assays.
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space and therefore should be protected from trypsin, was not
digested, thus validating the assay conditions. A small fraction
of p53, however, remained protected even after 20 min diges-
tion (compare lanes 2 with 4 and 6), indicating intraorganellar
location of a small subfraction of mitochondrial p53. This
might represent the subfraction of mitochondrial p53 engaged
in the in vivo complex with mitochondrial mt hsp70 protein
which we previously described [26].
3.3. p53 associates with mitochondria in vitro
The association of p53 with mitochondria was also repro-
ducible in vitro (Fig. 3A). When intact mitochondria isolated
from ML-1 cells were incubated with puri¢ed baculoviral hu-
man wt p53 or recombinant human PCNA protein (lanes 1,
2), only p53 but not PCNA became associated with mitochon-
dria, as determined by co-sedimentation with the organelles
(lanes 3, 4). Mock incubation without mitochondria ruled out
self-precipitation of baculoviral p53 (lane 5). Moreover, the
associated p53 was largely trypsin sensitive, but again showed
a small amount of protected p53 (Fig. 3B, lanes 1 and 2),
thereby recapitulating the situation already seen with endog-
enous mitochondria (Fig. 2).
4. Discussion
Our data show that a fraction of induced p53 protein spe-
ci¢cally localizes to mitochondria at the onset of hypoxia-
mediated apoptosis. In addition to true hypoxia, a condition
which frequently exists within solid tumors, we show that the
chemical hypoximimetic deferoxamine [28] also induces tar-
geting of endogenous p53 to mitochondria. DXE induces
apoptosis [31^33]. It acts within the O2 tension signal trans-
duction pathway [34] by chelating ferrous iron and might
function by displacing ferrous iron from the porphyrin ring
of the putative mammalian hemoprotein O2 sensor [35]. DXE
is a hypoximimetic because it activates hypoxia-inducible
transcription factor 1K activity (HIF-1K) and stimulates tran-
scription of hypoxia-associated genes including VEGF and
erythropoietin [32,35,36]. However, the mode of action di¡ers
between true hypoxia and DXE. Evidence suggests that mito-
chondrial ROS are necessary and su⁄cient for stabilization of
HIF-1K during true hypoxia (1% O2). In contrast, DXE re-
sponses require neither the mitochondria nor ROS, suggesting
that DXE acts at a more distal step in the hypoxia signaling
pathway [37]. Importantly, DXE induces transcriptionally ac-
tive p53 in a HIF-1K-dependent fashion, possibly via direct
complex formation between p53 and HIF-1K proteins [32].
This report is the ¢rst direct in vivo demonstration of the
targeting response of endogenous mitochondrial p53. Mito-
chondrial p53 translocation can be visualized by immuno£uo-
rescence at 6 h on whole cells, before p53 has reached its
maximum accumulation in the nucleus (see Fig. 1B). This
timeframe is consistent with our previous subfractionation
results after camptothecin, where mitochondrial p53 is highest
after 6 h [26]. Moreover, the in vivo targeting response could
be reproduced in vitro with isolated mitochondria and puri-
¢ed p53, suggesting that p53 might bind to protein compo-
nent(s) at the mitochondrial surface. In keeping with this no-
tion, our trypsin data suggest that p53’s main location in
mitochondria is on the surface. Limited digestion of isolated
mitochondria from stressed cells (Fig. 2) as well as from mi-
tochondria bound to puri¢ed p53 in vitro (Fig. 3B) shows that
the majority of mitochondrial p53 is digested with kinetics
similar to bcl-xL, an outer membrane-associated anti-apopto-
tic bcl member. The relationship of the surface-associated p53
and the subfraction of mitochondrial p53 that complexes with
mt hsp70 in vivo [26] will require further investigation. One
possibility is that p53 has an additional intraorganellar com-
partment which involves a transient import step by mt hsp70,
followed by subsequent resorting to the ¢nal compartment.
Interestingly, an amphipathic N-terminal import leader pep-
tide is not essential for import, as indicated by cytochrome c
which is located at the outer face of the inner membrane and
also lacks this sequence [38].
Following our initial description [26], a second nuclear tran-
scription factor, the orphan nuclear steroid receptor TR3 (also
called Nur77 or NGFIB), was also found to translocate to
mitochondria in response to a wide variety of pro-apoptotic
signals where it triggers membrane permeability and apoptotic
Fig. 3. In vitro localization assay of p53. A: Isolated mitochondria
(37 mg total protein) from ML-1 cells were incubated at 37‡C for
1 h with highly puri¢ed (silver gel pure) untagged baculoviral hu-
man wt p53 or recombinant PCNA (60 ng each). Proteins associ-
ated with mitochondria were recovered by pelleting, followed by
three washes in MS bu¡er (lanes 3 and 4). Lane 5 is identical to
lane 3 except that mitochondria were omitted, con¢rming that bac
p53 cannot precipitate by itself. As control, 1/10 of the input ali-
quots was loaded directly onto the gel (lanes 1 and 2). B: In vitro
associated mitochondrial p53 before (lane 1) and after trypsin diges-
tion (lane 2). Conditions as in Fig. 2. As control, 1/5 of the input
aliquots before (lane 4) and after (lane 3) trypsin digestion was
loaded directly onto the gel. Bovine serum albumin (BSA) is used
to substitute for mitochondrial proteins.
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cell death. As is true for mitochondrial p53, mitochondrial
TR3 is su⁄cient to cause cell death and its action is blocked
by bcl-2 [39]. Thus, there might be now two nuclear transcrip-
tion factors that, by virtue of their subcellular relocalization,
are capable of mediating lethal signaling directly through mi-
tochondria [40]. In the case of p53, its mitochondrial action
likely enhances the transcriptional action of nuclear p53 to
mediate cell death.
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